Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Stagezero Life Sciences Ltd (SZLS.TO)

Stagezero Life Sciences Ltd (SZLS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Stagezero Life Sciences Ltd 70 East Beaver Creek Road Unit 30 Richmond Hill ON L4B 3B2 CAN

https://www.stagezerolifesciences.com P: 905-209-2030

Description:

StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.

Key Statistics

Overview:

Market Capitalization, $K 4,909
Shares Outstanding, K 105,465
Annual Sales, $ 3,795 K
Annual Net Income, $ -11,415 K
Last Quarter Sales, $ 745 K
Last Quarter Net Income, $ -822 K
60-Month Beta -0.05
% of Institutional Shareholders 0.18%

Growth:

1-Year Return -55.56%
3-Year Return -94.67%
5-Year Return -96.15%
5-Year Revenue Growth 55.93%

Per-Share Information:

Latest Earnings Date 05/20/24
Earnings Per Share ttm -0.12
EPS Growth vs. Prev Year 74.99%
Dividend Payout Ratio 0.00%
Most Recent Split 1-8 on 09/18/20

SZLS.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % -281.22%
Profit Margin % -300.79%
Debt/Equity N/A
Price/Sales 1.11
Price/Book N/A
Book Value/Share -0.10
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar